PlumeStars and Biopharmanet-Tec will attend together with the company Lisapharma spa The Eight World Congress of Orphan Medicines, in Barcelona on 14 and 15 November 2017.
The Congress brings together companies, start-ups and stakeholders in the field of orphan diseases and rare diseases.
Read more “14-15 November: the Eight World Congress of Orphan Medicinal Products in Barcelona”
Cardiovascular diseases, such as myocardial infarct and heart failure, represent a societal burden, accounting for more than 30% of deaths globally and spending yearly ~190 billion € in European healthcare. The chronic treatment of patients leads only to short-term benefits, since the conventional therapies show several weak points.
Read more “The nano-revolution reaches the heart: the EU-funded project CUPIDO”
Among the number of diseases affecting people, there are some that affect few individuals. Consequently, there is no interest from pharmaceutical companies to study and develop drugs and medicines, since it prevails the equation: few patients, few earnings.
But this was a temporally referable reality at the beginning of the millennium: rare diseases were called “orphans” because they were orphans of research, treatment and investment. But now everything has changed and we are witnessing, for some years now, a real revolution.
As reported in the Italian newspaper La Repubblica of February 26, 2019 “the supports of EU and USA for these forgotten diseases have turned the problem into an opportunity. The rare disease market, with therapies that cost an average of $ 140,000 a year per patient, have become the new goldmine of the drug giants “.
In this regard, always La Repubblica, reports the brilliant experience of the Swiss firm Roche that has bought for 4.8 billion Spark Therapeutics: The American company “has only 250 employees and 68 million of revenues in 2018 (more or less like a SME). However, it has one of the most promising products in the world of orphan drugs: Luxturna, a product able to avoid blindness in some serious eye conditions. The patients affected by this disease are not many, but the cost of therapy – about $ 450 thousand – added to the public subsidies, have made possible to discover, develop and get approved a medicine at cost of about 700 million. Thus, the small Spark turned into a jewel of multibillion dollar value”.
The rare diseases become a new business for pharmaceutical giants.
Read the article of La Repubblica 26-02-2019
PlumeStars participated at the conference “Open & Science Innovation” held on 25th February at Milan.
The conference, promoted by Airi – Italian Association for Industrial Research aims to highlight some cooperation practices between industrial and public research, characterized by quality and novelty, as well as possibilities for technological transfer methodologies and tools.
Read more “PLUMESTARS ATTENDED AT “OPEN AND SCIENCE INNOVATION” CONFERENCE”
PlumeStars is pleased to inform you that Professor Ruggero Bettini, member of the company, has been elected to the American Institute for Medical and Biological Engineering (AIMBE) College of Fellows.
AIMBE is a non-profit, honorific society of the most accomplished individuals in the fileds of medical and biological engineering. AIMBE’s missions is to advocate for biomedical engineering innovation through public policy initiatives.
No other organization brings together academia, industry, government, and scientific societies into a highly influential community in medical and biological engineering.
Being part of the AIMBE College of Fellows enables intimate networking and public policy engagement among trailblazers at the pinnacle of their careers.
on behalf of the PlumeStars’s Team wish you a wonderful holiday season and a happy new year!
PlumeStars actively participated at the DDL 2018 , Drug delivery to the Lungs conference held on 12, 13 and 14 December at Edinburgh.
The Drug Delivery to the Lungs conference (DDL) is Europe’s premier conference and industry exhibition which is dedicated to pulmonary and nasal drug delivery.
Read more “PlumeStars attended at the DDL 2018”
PlumeStars actively participated at the 58th AFI Symposium, the Italian Conference of the Industrial Pharmacists, held on 6, 7 and 8 June at the Pala Congressi in Rimini. The symposium has registered more than 1000 attendees and more than 100 stands, reconfirming itself as a meeting point for excellence which revolves around the pharmaceutical world.
Read more “PlumeStars attended the 58th AFI Symposium”
When: 16 May 2018
Where: Aula Magna, Via Università 12, Parma (Italy)
Subject: Pre-conference workshop “Medicines for rare diseases”
Read more “16 May: Pre-conference workshop “Medicines for rare diseases” , in collaboration with University of Parma”
When: 12-13 April 2018
Where: Pharmacy Building (Room C), Campus Univeristy of Parma, Viale Parco Area delle Scienze 27/A (Pr)
Subject:Quality by Design in Pharmaceutical Development: theory and case studies
Read more “12-13 April: Two Day seminar QbD, in collaboration with University of Parma”
In occasion of the Annual Conference of the European Association of Pharmacy 2018: 16-18 May, Parma, Italy, the Food and Drug Department of the University of Parma, in collaboration with the Innovative SME PlumeStars, announces the organization of the Pre-Conference Workshop Medicines for rare diseases, Wednesday, May 16th, 2018, Aula Magna, Via Università 12, Parma, Italy.
Read more “May 16th 2018: Pre-Conference Workshop “Medicines for rare diseases”, in collaboration with University of Parma”